Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | September 15, 2026 | September 15, 2026 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | February 02, 2024 | February 06, 2024 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,184 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 1,000 · Balance 8,184 |
REGENERON PHARMACEUTICALS, INC.
Report date February 02, 2024 · Filed February 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,693 |
Ending reported balance
After 2024-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-02 · Exercise / conversion · Acquired 400 · Balance 23,974 Row 2 · 2024-02-02 · Tax withholding · Disposed 281 · Balance 23,693 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $378.98 · Expires 2027-12-12 | Direct | 11,787 |
Reported balance
After 2024-02-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-02 · Exercise / conversion · Disposed 400 · Balance 11,787 F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 270 |
Reported balance
Holding disclosure · report date 2024-02-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 270 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 23, 2023 Filed Aug 25, 2023 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 223 | $844.00 | $188,212.00 |
DisclosureSEC source: 0001968202-23-000030 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,699 Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 31 | $826.36 | $25,617.16 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 20 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,922 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 243 | $825.37 | $200,564.91 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 19 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,953 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F11 · price: Represents volume-weighted average price of sales of 243 shares of Company stock on March 28, 2023 at prices ranging from $825.02 to $825.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 157 | $824.54 | $129,452.78 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 18 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,196 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F10 · price: Represents volume-weighted average price of sales of 157 shares of Company stock on March 28, 2023 at prices ranging from $824.00 to $824.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 181 | $823.60 | $149,071.60 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 17 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,353 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F9 · price: Represents volume-weighted average price of sales of 181 shares of Company stock on March 28, 2023 at prices ranging from $823.02 to $823.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 128 | $822.67 | $105,301.76 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 16 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,534 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F8 · price: Represents volume-weighted average price of sales of 128 shares of Company stock on March 28, 2023 at prices ranging from $822.21 to $822.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 142 | $821.40 | $116,638.80 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 15 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,662 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F7 · price: Represents volume-weighted average price of sales of 142 shares of Company stock on March 28, 2023 at prices ranging from $821.04 to $821.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 115 | $820.85 | $94,397.75 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 14 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,804 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F6 · price: Represents volume-weighted average price of sales of 115 shares of Company stock on March 28, 2023 at prices ranging from $820.67 to $820.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 28, 2023 at each separate price. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $818.81 | $8,188.10 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 13 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,919 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 800 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · derivative · entry 23 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800 shares Expires 2026-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F12 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $378.98 | $0.00 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · derivative · entry 22 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,337 Underlying: Common Stock · 3,000 shares Expires 2027-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F12 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $830.01 | $5,810.07 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 12 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,929 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $829.16 | $3,316.64 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 11 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,936 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13 | $825.59 | $10,732.67 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 10 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,940 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $824.30 | $3,297.20 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,953 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $822.57 | $14,806.26 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,957 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F5 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on March 27, 2023 at prices ranging from $822.46 to $822.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 27, 2023 at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 48 | $821.39 | $39,426.72 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,975 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F4 · price: Represents volume-weighted average price of sales of 48 shares of Company stock on March 27, 2023 at prices ranging from $821.02 to $821.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 27, 2023 at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 50 | $820.46 | $41,023.00 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,023 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F3 · price: Represents volume-weighted average price of sales of 50 shares of Company stock on March 27, 2023 at prices ranging from $820.00 to $820.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 27, 2023 at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 39 | $819.47 | $31,959.33 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,073 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. F2 · price: Represents volume-weighted average price of sales of 39 shares of Company stock on March 27, 2023 at prices ranging from $819.34 to $819.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 27, 2023 at each separate price. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,204 | $825.17 | $1,818,674.68 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,112 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $378.98 | $1,136,940.00 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 589 | $825.17 | $486,025.13 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,316 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 800 | $381.92 | $305,536.00 |
DisclosureSEC source: 0001968202-23-000004 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 24, 2023. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 28 | $797.43 | $22,328.04 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 17 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,105 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $796.43 | $14,335.74 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 16 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,133 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on February 6, 2023 at prices ranging from $796.35 to $796.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 59 | $795.41 | $46,929.19 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 15 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,151 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 59 shares of Company stock on February 6, 2023 at prices ranging from $795.26 to $795.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 99 | $794.61 | $78,666.39 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 14 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,210 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 99 shares of Company stock on February 6, 2023 at prices ranging from $794.28 to $794.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $793.33 | $1,586.66 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 13 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,309 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $791.00 | $2,373.00 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 12 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,311 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $790.41 | $7,904.10 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 11 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,314 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 49 | $789.05 | $38,663.45 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 10 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,324 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 99 | $788.62 | $78,073.38 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 9 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,373 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 99 shares of Company stock on February 6, 2023 at prices ranging from $788.48 to $788.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 58 | $787.47 | $45,673.26 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 8 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,472 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 85 | $786.45 | $66,848.25 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 7 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,530 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 85 shares of Company stock on February 6, 2023 at prices ranging from $786.03 to $786.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 78 | $785.88 | $61,298.64 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 6 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,615 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 78 shares of Company stock on February 6, 2023 at prices ranging from $785.85 to $785.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 113 | $784.27 | $88,622.51 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,693 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 113 shares of Company stock on February 6, 2023 at prices ranging from $784.02 to $784.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 51 | $783.05 | $39,935.55 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,806 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · derivative · entry 19 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 3,000 shares Expires 2026-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,248 | $774.29 | $1,740,603.92 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,857 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $381.92 | $1,145,760.00 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 739 | $764.50 | $564,965.50 |
DisclosureSEC source: 0001883850-23-000035 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,105 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,222 | $0.00 Strike: $726.53 | $0.00 |
DisclosureSEC source: 0001883850-22-000132 · edgardoc.xml · derivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,222 Underlying: Common Stock · 14,222 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 3,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000132 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,844 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 21:34 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 492 | $753.28 | $370,613.76 |
DisclosureSEC source: 0001883850-22-000107 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,991 Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:34 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001883850-22-000107 · edgardoc.xml · derivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Underlying: Common Stock · 3,000 shares Expires 2026-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:34 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,261 | $768.54 | $1,737,668.94 |
DisclosureSEC source: 0001883850-22-000107 · edgardoc.xml · nonDerivative · entry 2 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,483 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:34 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,000 | $381.92 | $1,145,760.00 |
DisclosureSEC source: 0001883850-22-000107 · edgardoc.xml · nonDerivative · entry 1 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $760.19 | $9,122.28 |
DisclosureSEC source: 0001883850-22-000102 · edgardoc.xml · nonDerivative · entry 5 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,744 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 16 | $759.90 | $12,158.40 |
DisclosureSEC source: 0001883850-22-000102 · edgardoc.xml · nonDerivative · entry 4 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,756 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 02, 2022 Filed Dec 2, 2022 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 582 | $756.50 | $440,283.00 |
DisclosureSEC source: 0001883850-22-000102 · edgardoc.xml · nonDerivative · entry 3 Landry Robert E · CIK 0001585160 · EVP Finance CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,772 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.